|
|
Post by thekindaguyiyam on Jan 6, 2016 13:51:16 GMT -5
|
|
|
|
Post by joeypotsandpans on Jan 7, 2016 13:19:03 GMT -5
Best article from the LA Times yet, the quote directly from the physician about SNY's half assed approach is priceless and very foretelling of what will emerge down the road IMO. Matt was constrained by the board on what he could say in his brief conference call. I expect at the very least a kiss goodbye payment...read the blatantly defensive statement from the SNY spokesperson regarding their "efforts" in promoting the still mostly unknown to diabetics product...and the physicians response regarding same. If I was an attorney in the appropriate field I would be begging/knocking on MNKD's door AYFKM!! |
|
|
|
Post by mnholdem on Jan 7, 2016 13:37:56 GMT -5
A fair, well-written piece that, at least, suggests that is was a botched distributor rollout, not the drug, that hindered initial results. I sure would like to hear former CEO Chris Veihbacher talk about it, but he likely has to obey some kind of nondisclosure agreement as part of his Sanofi severance package. Mann learned the hard way not to pick any BP that has a conflict of interests.
Regardless, I think that MannKind will have a new partner before long. BPs are a greedy bunch.
|
|
|
|
Post by bradleysbest on Jan 7, 2016 13:41:34 GMT -5
I hope so, we need a partner ASAP! Someone has to see thru the BS & realize the potential Afrezza has.
|
|
|
|
Post by peppy on Jan 7, 2016 13:51:17 GMT -5
In an emailed statement, Sanofi spokeswoman Susan Brooks said the company didn't scrimp on promoting Afrezza. She said Sanofi worked to help patients with the insurance reimbursement process, worked with doctors to address lung-testing requirements and offered educational seminars.
Despite all that, "Afrezza has continued to demonstrate low volume and revenue performance," she said. ------- Marcus, the Laguna Hills endocrinologist, said Sanofi's educational and marketing efforts fell short, "Sanofi didn't have a wise plan for introducing this product," he said.
What's more, Marcus said many of the patients he prescribed Afrezza to ended up dropping it because it wasn't covered by their insurance.
Keith Markey, an analyst at Griffin Securities in New York, said Sanofi was not able to get many insurance companies to accept Afrezza, making it difficult for many patients to afford the drug.
"It was an extremely slow and cumbersome process for everyone involved. If you can't get the drug, you can't find out that it's really easier to use" than injections, Markey said.
------------------- Excellent article
|
|
